Lopinavir/Ritonavir as an Immunomodulator to Enhance Vaccine Responsiveness

Inclusion Criteria:

- Adult subjects who are in complete remission at Day +100 after a bone marrow
transplant for Hodgkins Lymphoma

- Normal AST or ALT, serum creatinine and 12-lead electrocardiogram within the previous
6 months

- Females of childbearing potential must have negative beta-HCG (urine or plasma)
within the last month and agree to effective contraception during the course of the
study

- Willingness and ability to give informed consent

- Willingness and ability to take pills twice a day for 28 days

Exclusion Criteria:

- Known HIV positive

- Screening ALT or AST greater than 3X upper limit of normal

- Baseline QTc greater than 500 msec

- Current treatment with immunosuppressive agent (systemic glucocorticoid,
cyclosporine, mycophenolate, azathioprine, sirolimus, Rituximab, infliximab,
adalimumab)

- Current treatment with any of the following: cisapride, ergot derivatives,
amiodarone, quinidine, terfenadine, astemizole, rifampin/rifabutin, carbamazepine,
phenobarbital, sildenafil, St. John's wort, azithromycin, carbamazepine, HIV
anti-virals, methadone, pimozide, phenytoin, sedative hypnotics (midazolam,
triazolam), HMG-CoA reductase inhibitors (lovastatin, simvastatin, atorvastatin)

- Active malignancy requiring chemotherapy or radiation

- Baseline creatinine of > 2.0

- Active infection requiring systemic anti-infective agent (excluding prophylactic
antibiotics)

- Hypersensitivity to processed bovine gelatin, chicken protein, neomycin, amphotericin
B or chlortetracycline

- Subject must not be on medications that interact with the metabolism of protease
inhibitors